Recent developments for CERo Therapeutics include clinical progress in its Phase 1 trial of CER-1236 for acute myeloid leukemia, regulatory milestones such as FDA Fast Track and Orphan Drug designations, capital raising through convertible promissory notes, and multiple buy recommendations from analysts.

• CERo Therapeutics completed initial patient evaluation in Phase 1 clinical trial of CER-1236 for acute myeloid leukemia, reporting no dose-limiting toxicities in the first patient [N6][N5].
• The FDA granted Fast Track designation to CER-1236, facilitating expedited development and review [N4].
• CERo received Orphan Drug designation from the FDA for CER-1236 in acute myeloid leukemia treatment [N7][N8].
• The company issued multiple convertible promissory notes to Keystone Capital Partners, LLC, with aggregate borrowing capacity up to $1 million, bearing 10% interest and convertible into common stock [S1].
• CERo was delisted from Nasdaq effective October 31, 2025, following a hearing panel decision and subsequent appeal affirming the delisting [S1].
• Following fundraising efforts, CERo regained compliance with Nasdaq listing rules [N1].
• Analysts from D. Boral Capital and Maxim Group have maintained buy recommendations on CERo Therapeutics [N1][N2][N3].

CERo has demonstrated clinical progress with CER-1236 in Phase 1 trials, reporting no dose-limiting toxicities and completing initial patient evaluations. The FDA Fast Track and Orphan Drug designations for CER-1236 in acute myeloid leukemia highlight regulatory support that may facilitate expedited development and potential market exclusivity. The company’s expanding patent portfolio strengthens its intellectual property position. Recent successful fundraising and regained Nasdaq compliance provide financial resources to support ongoing development. Positive analyst coverage and buy recommendations reflect market interest in CERo's therapeutic potential.

CERo faces significant liquidity constraints, with a current ratio of 0.3 and cash ratio of 0.21 as of December 31, 2025, indicating limited short-term financial flexibility. The company reported a substantial net loss of nearly $20 million in 2025, reflecting high operating costs typical of clinical-stage biopharma firms. Delisting from Nasdaq in late 2025 may impact investor access and liquidity. The success of CER-1236 and other pipeline candidates remains uncertain, with clinical and regulatory risks inherent in drug development. Dependence on convertible notes and capital raises introduces dilution and financial risk.

CERo's moat is primarily based on its proprietary immunotherapy technology platform and its lead candidate CER-1236, which has received FDA Fast Track and Orphan Drug designations, providing regulatory advantages and potential market exclusivity. The company's portfolio of 18 patents and applications further protects its intellectual property. The clinical progress and regulatory recognitions enhance CERo's position in the competitive oncology therapeutics space. However, as an emerging growth biopharma company, its moat is contingent on successful clinical development and eventual commercialization of its pipeline products.

• Liquidity Risk: The company’s current ratio of 0.3 and cash ratio of 0.21 as of December 31, 2025, indicate limited liquidity, which may constrain operational flexibility and require additional financing.
• Clinical and Regulatory Risk: CERo’s lead candidate CER-1236 is in early-stage clinical trials, and its ultimate safety, efficacy, and regulatory approval remain uncertain.
• Market and Listing Risk: Delisting from Nasdaq in October 2025 and reliance on private placements and convertible notes may affect investor confidence and market access.
• Operational Risk: As an emerging growth biopharma company, CERo faces risks related to execution of clinical development, intellectual property protection, and management of expenses.

• CERo Therapeutics Holdings, Inc. is a Delaware corporation headquartered in South San Francisco, CA.
• The company is an emerging growth company and is not listed on any major exchange; its common stock (CERO) and warrants (CEROW) are not listed on Nasdaq or other exchanges.
• CERo focuses on biopharmaceutical development, with a lead candidate CER-1236 targeting acute myeloid leukemia (AML).
• CER-1236 has received FDA Fast Track designation and Orphan Drug designation for AML treatment.
• The company has conducted a Phase 1 clinical trial of CER-1236, with initial patient evaluation completed and no dose-limiting toxicities reported in the first patient.
• CERo holds 18 patents and applications expanding its immunotherapy portfolio.
• The company has undergone a one-for-twenty reverse stock split effective June 13, 2025.
• CERo has issued multiple convertible promissory notes to Keystone Capital Partners, LLC, with aggregate borrowing capacity up to $1 million, bearing 10% interest and convertible into common stock at specified conversion prices.
• As of December 31, 2025, CERo had cash and equivalents of approximately $1.9 million and current assets of about $2.73 million, with current liabilities of approximately $9.09 million, resulting in a current ratio of 0.3 and a cash ratio of 0.21, indicating liquidity constraints.
• The company reported a net loss of approximately $19.9 million for the fiscal year ended December 31, 2025, and a basic and diluted EPS of -$9.10 as of September 30, 2025.
• CERo's board of directors consists of seven members with staggered three-year terms, including Chairman and CEO Chris Ehrlich since December 2024.
• The company has regained compliance with Nasdaq listing rules following successful fundraising efforts but was delisted from Nasdaq effective October 31, 2025, after appeals.
• CERo's management includes experienced executives with backgrounds in biotechnology, venture capital, and pharmaceutical development.
• Recent news coverage includes multiple buy recommendations from D. Boral Capital and Maxim Group, clinical updates on CER-1236, and regulatory milestones such as FDA Fast Track and Orphan Drug designations.